Aurinia Pharmaceuticals Inc.

Aurinia is a biopharmaceutical company that develops and commercializes therapies for autoimmune diseases with high unmet medical needs. The company's primary revenue source is LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis, which it markets directly in the United States through a specialty pharmacy network and in international markets through a collaboration with Otsuka Pharmaceutical. Beyond LUPKYNIS, Aurinia is developing aritinercept, a dual inhibitor of BAFF and APRIL for potential treatment of multiple autoimmune diseases currently in clinical trials.